Company Financial Calendar
| Event |
Date |
| Half year end |
30th June |
| Interim results announced |
September |
| Financial year end |
31st December |
| AGM |
TBD |
Company Financial Reports
Annual Report 2007
Medgenics Admission Document December 2007
Regulatory Disclosures, Announcements and Notifications
July 31, 2008: Medgenics Granted Approval to Commence Its Phase I/II Clinical Study of EPODURE to treat Anemia
July 4, 2008: Response from ISRAEL’S Ministry of Health on its Phase I/II clincal Trial with EPODURE in Anemia
June 30, 2008: Notification of transactions of directors, persons discharging managerial responsibility or connected persons
June 30, 2008: Issue of Equity Total Voting Rights
June 19, 2008: Medgenics announces preliminary results for the year ended 31 December 2007
June 4, 2008: Block Listing Interim Review
May 7, 2008: Medgenics appoints vice president of Clinical Affairs
Apr 30, 2008: Total Voting Rights
Apr 22, 2008: Announcement re Issue of Equity
Apr 14, 2008: Research Update: Medgenics on target to start Phase I/II clinical trials with EPODURE protein therapy for anaemia mid-2008 as planned
Mar 18, 2008: Medgenics consolidates corporate and R&D operations into new office facility
Feb 1, 2008: Lord Steinberg Appointment
Dec 4, 2007: Medgenics Admission to Trading
Dec 4, 2007: Medgenics Block Admission and ISIN update
Preliminary Announcement of AIM Submission
|
|
